Autopsy report · NCT00286169
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- 130 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Small-cell Lung Cancer
- Interventions
- Amrubicin Hydrochloride
- Participants
- 130 (planned, not actual)
- Sites
- 8
- Countries
- Japan
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.